CKM Syndrome: What Does Early Inflammation Reveal?

What did the study find about early CKM inflammation?

Researchers examined National Health and Nutrition Examination Survey data collected during 2015–2018. Average hs-CRP was almost twice as high at stage 1 as at stage 0, increased further at stage 2, and then changed little across later stages. The University of Eastern Finland highlighted the findings in October following publication in the European Journal of Preventive Cardiology. These were comparisons between groups, rather than measurements of individuals progressing through disease. [University research announcement](https://oembed.uef.fi/en/article/inflammation-is-already-elevated-at-the-earliest-stage-of-cardiovascular-kidney-metabolic-syndrome).

The analysis excluded people with hs-CRP above 10 mg/L to reduce the influence of acute inflammation. However, a single measurement cannot reliably distinguish every temporary increase from persistent inflammation. The observational design also leaves uncertainty about cause and effect: it cannot establish whether inflammation preceded metabolic changes or predict which participants will develop complications. Medication use and other differences between groups may influence the pattern. [Original study](https://doi.org/10.1093/eurjpc/zwag476).

What does hs-CRP reveal about heart and kidney health?

C-reactive protein is made by the liver in response to inflammatory signals. The high-sensitivity test detects smaller concentrations useful in cardiovascular risk assessment. An elevated result does not identify where inflammation originates: infections and inflammatory diseases can also increase CRP. Consequently, a result needs interpretation alongside medical history and other findings; it does not establish that someone has heart disease or kidney damage. [MedlinePlus explanation of CRP](https://medlineplus.gov/ency/article/003356.htm).

The CKM framework connects cardiovascular health, kidney function and metabolism. Stage 0 describes the absence of identified risk factors. Stage 1 includes excess or dysfunctional body fat and may include prediabetes, while subsequent stages encompass conditions such as hypertension, diabetes, kidney disease and cardiovascular disease. This explains why an inflammatory signal can appear before established organ disease. A person's stage reflects their current health and can improve with appropriate care. [American Heart Association CKM guide](https://www.heart.org/en/health-topics/cardiovascular-kidney-metabolic-syndrome/a-guide-to-cardiovascular-kidney-metabolic-health).

How should the findings influence prevention and testing?

Current CKM guidance emphasizes assessing metabolic risk factors and kidney health together. Depending on the clinical situation, assessment includes blood pressure, cholesterol, blood glucose, estimated kidney filtration and urine albumin, which can reveal kidney damage. The practical implication is that an inflammation result should sit within this broader evaluation. Treatment decisions depend on established conditions and expected cardiovascular or kidney benefits. [American Heart Association guideline summary](https://professional.heart.org/en/science-news/2026-guideline-for-the-prevention-detection-evaluation-and-management-of-ckm-syndrome/top-things-to-know).

Established prevention measures include regular movement, a nutritious eating pattern, avoiding tobacco, adequate sleep and support for managing weight, blood pressure and blood sugar. These measures address several connected risks. The new study did not test a treatment, and whether inflammation-directed therapy prevents early CKM progression remains a research question. Its immediate relevance is to reinforce early assessment and coordinated preventive care. [American Heart Association prevention guidance](https://www.heart.org/en/health-topics/cardiovascular-kidney-metabolic-syndrome/a-guide-to-cardiovascular-kidney-metabolic-health), [study findings and limitations](https://doi.org/10.1093/eurjpc/zwag476).